IndraLab

Statements

Hydroxychloroquine inhibits HR. 6 / 6
| 6
reach
"After adjusting for confounders, hydroxychloroquine was protective of renal damage occurrence in full (HR = 0.12; 95% CI 0.02-0.97; p = 0.0464) and reduced (HR = 0.29; 95% CI 0.13-0.68; p = 0.0043) models."
19479701
reach
"Long-term HCQ therapy may decrease the HR of CAD in SS patients."
33126508
reach
"Hydroxychloroquine use reduced the risk of death (HR = 0.46, 95% CI 0.29 to 0.72, p < 0.05) and renal damage (HR = 0.30, 95% CI 0.13 to 0.68, p < 0.05)."
33832976
reach
"Male sex (hazard ratio [HR] 2.42, p < 0.01), end-stage renal disease (ESRD; HR 1.74, p = 0.01), recent use of mycofenolate mofetil (MMF; HR 4.43, P < 0.001), intravenous steroid pulse therapy (HR 108.73, p < 0.001), and average oral dose of> 7.5 mg/day prednisolone or equivalent (HR 4.83, p < 0.001) were associated with PJP in SLE, whereas hydroxychloroquine use reduced its risk (HR 0.51, p = 0.01)."
33645012
reach
"HCQ reduced the risk of infection (HR 0.73)."
34042053
reach
"After adjusting for confounders, hydroxychloroquine was protective of renal damage occurrence in full (hazard ratio [HR] 0.12, 95% confidence interval [95% CI] 0.02-0.97, P = 0.0464) and reduced (HR 0.29, 95% CI 0.13-0.68, P = 0.0043) models."
19479701